Human Siglec-2/CD22 Antibody

Catalog #: MAB19682 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB19682-100
MAB19682-SP

Cell Adhesion Mediated by Siglec-2/CD22 and Neutralization by Human Siglec-2/CD22 Antibody.

1 Image

Product Details

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human Siglec-2/CD22 Antibody Summary

Species Reactivity

Human

Specificity

Detects human Siglec-2/CD22 in direct ELISAs.

Source

Monoclonal Mouse IgG_2B Clone # 219903

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Mouse myeloma cell line NS0-derived recombinant human Siglec-2/CD22
Asp20-Arg687
Accession # P20273

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Neutralization

Measured by its ability to neutralize Siglec‑2/CD22-mediated adhesion of human red blood cells. Kelm, S. et al. (1994) Current Biology 4:965. The Neutralization Dose (ND₅₀) is typically 6-60 ng/mL in the presence of 0.2 µg/mL Recombinant Human Siglec‑2/CD22 Fc Chimera.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization

View Larger

Cell Adhesion Mediated by Siglec-2/CD22 and Neutralization by Human Siglec-2/CD22 Antibody. Recombinant Human Siglec-2/CD22 Fc Chimera (Catalog # 1968-SL), immobilized onto a microplate, supports the adhesion of human red blood cells in a dose-dependent manner (orange line) as measured by the psuedoperoxidase assay. Adhesion elicited by Recombinant Human Siglec-2/CD22 Fc Chimera (0.2 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human Siglec-2/CD22 Monoclonal Antibody (Catalog # MAB19682). The ND₅₀ is typically 6-60 ng/mL.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Siglec-2/CD22

Siglecs (Sialic acid binding Ig-like Lectins) are I-type (Ig-type) lectins belonging to the Ig superfamily. They are characterized by an N-terminal V-type Ig-like domain which mediates sialic acid binding, followed by varying numbers of C2-type Ig-like domains (1, 2). Fourteen human Siglecs have been cloned and characterized. They are Sialoadhesin/CD169/Siglec-1, CD22/Siglec-2, CD33/Siglec-3, Myelin-Associated Glycoprotein (MAG/Siglec-4a), and the identified Siglecs 5 to 11, plus 14 to 16 (1-3). To date, no Siglec has been shown to recognize any cell surface ligand other than sialic acid, suggesting that interactions with glycans containing this carbohydrate are important in mediating the biological functions of Siglecs. Human Siglec-2, also known as B-cell antigen CD22 or B lymphocyte cell adhesion molecule (BL-CAM), is a B cell restricted glycoprotein that is expressed in the cytoplasm of progenitor B and pre-B cells and on the surface of mature B cells and intestinal eosinophils (3,4). Two distinct human Siglec-2/CD22 cDNAs that arise from differential RNA processing of the same gene have been isolated. The predominant Siglec-2/CD22 beta encodes an 847 amino acid (aa) polypeptide with a hydrophobic signal peptide, an V-type N-terminal Ig-like domain, six C2-type Ig-like domains, a transmembrane region and a cytoplasmic tail with 4 immunoreceptor tyrosine-based inhibition motifs (ITIMs) (5). The variant Siglec-2/CD22 alpha encodes a 647 aa polypeptide missing two C2-type Ig-like domains and has a truncated (23 aa) cytoplasmic tail (6). Siglec-2/CD22 is an adhesion molecule that preferentially binds alpha 2,6- linked sialic acid on the same (cis) or adjacent (trans) cells. Besides its role as an adhesion molecule, Siglec-2/CD22 is a coreceptor that physically interacts with B cell receptor (BCR) and is rapidly phosphorylated upon BCR ligation (3). It negatively regulates BCR signals by recruiting tyrosine phosphatase SHP-1 to its ITIMs, likely within large oligomeric complexes. Over aa 20-687, human and mouse share 59% aa sequence identity.

References

Magesh, S. et al. (2011) Curr. Med. Chem. 18:3537.
Bocher, B.S.. and N. Zimmermann (2015) J. Allergy Clin. Immunol. 135:598.
Nitschke, L. (2014) Glycobiology 24:807.
Wen, T. et al. (2012) J. Immunol. 188:1075.
Wilson, G.L et al. (1991) J. Exp. Med. 173:137.
Stamenkovic, I. and B. Seed (1990) Nature 345:74.

Long Name

Sialic Acid Binding Ig-like Lectin 2

Entrez Gene IDs

933 (Human); 12483 (Mouse); 308501 (Rat); 102130968 (Cynomolgus Monkey)

Alternate Names

B-cell receptor CD22; BL-CAM; B-lymphocyte cell adhesion molecule; CD22 antigenMGC130020; CD22 molecule; CD22; sialic acid binding Ig-like lectin 2; Sialic acid-binding Ig-like lectin 2; Siglec2; Siglec-2; SIGLEC2FLJ22814; T-cell surface antigen Leu-14